Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma Limited.
The UK-based biopharmaceutical group has published a detailed shareholder circular alongside a Q&A document on its website, designed to clarify the rationale and implications of the move. Shareholders are being asked to vote on the proposals, which are positioned as part of a strategic shift to reduce regulatory costs and improve operational focus.
Ananda says the transition will allow greater flexibility and enable more efficient allocation of capital towards its core mission: the development of regulatory-approved cannabidiol (CBD) medicines targeting complex chronic conditions, including endometriosis and chemotherapy-induced pain.
The Company has received a number of questions from shareholders about the proposals to be considered at the General Meeting. Those questions and the answers from management can be found on the company’s website here: https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market
The company believes operating as a private entity will better support long-term clinical progress and funding strategy, while maintaining transparency and engagement with its shareholder base.
To stay up to date with Ananda’s news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
